Skip to content
AMGN·Nasdaq·US

Amgen

Amgen discovers, develops, manufactures and delivers innovative medicines for serious diseases, focusing on areas of high unmet medical need. It is one of the world's leading independent biotechnology companies, has a presence in approximately 100 countries, and sells in the United States substantially all through pharmaceutical wholesale distributors that supply healthcare providers.

Source: SEC 10-K Feb 13, 2026

Recent Activity

Updated Oct 31, 2026
–Amgen said its drug, when added to AstraZeneca's immunotherapy, cut the risk of death by 58% in patients with an aggressive form of lung cancer.

Past updates are part of the Pro plan.

Thematic Position

AMGN

Relationship Groups

Suppliers2
Customers7
Partners10
Licensing6
Competitors28

Relationship details are part of the Pro plan.

Recent Discoveries

Recent discoveries are part of the Pro plan.

Ended Relationships

1 ended relationship · Ended relationships are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

tarifftrade investigation
U.S. tariffs and Section 301 China investigation raise Amgen's production costs and supply chain risk
SEC 10-QMay 1, 2026

The full regulatory passage is part of the Pro plan.

15 more · Regulatory and geopolitical insights are part of the Pro plan.

Disclosed customers above 10% of revenue

3 customers · Named major customers are part of the Pro plan.